Vicore Pharma Holding AB (publ) (VICO.ST)
Develops experimental drugs and medical devices to treat lung diseases like pulmonary fibrosis
10.82-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+22.0%
The outlook
Vicore trades near the lower end of its 52-week range, well below both its 50- and 200-day averages. Analysts show strong conviction with a "Strong Buy" consensus and an average price target roughly 190% above the current level. The overall sentiment remains neutral despite the bullish analyst view, reflecting caution among the broader market.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 5 analysts
Price trendBelow its 50- & 200-day averages
52-week range23% of the way from its 52-week low to high
Price targetAvg target +190% vs current price
Analyst price target
~12-month · 5 analysts31.40average target+190.2% vs now
Now 10.82
Low 15.00High 40.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$3.05B
52-wk high
18.24
52-wk low
8.56
50-day avg
11.69
200-day avg
10.85
Trailing P/E
—